A detailed history of Arvest Trust CO N A transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Arvest Trust CO N A holds 35,482 shares of BMY stock, worth $1.89 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
35,482
Previous 38,173 7.05%
Holding current value
$1.89 Million
Previous $2.07 Million 28.84%
% of portfolio
0.1%
Previous 0.13%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$40.25 - $52.99 $108,312 - $142,596
-2,691 Reduced 7.05%
35,482 $1.47 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $157,134 - $178,160
3,275 Added 9.38%
38,173 $2.07 Million
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $429,241 - $512,203
-8,854 Reduced 20.24%
34,898 $1.79 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $39,538 - $44,210
-683 Reduced 1.54%
43,752 $2.54 Million
Q2 2023

Aug 15, 2023

SELL
$63.71 - $70.74 $199,985 - $222,052
-3,139 Reduced 6.6%
44,435 $2.84 Million
Q1 2023

May 11, 2023

BUY
$65.71 - $74.53 $236,490 - $268,233
3,599 Added 8.18%
47,574 $3.3 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $239,474 - $283,571
3,497 Added 8.64%
43,975 $3.16 Million
Q3 2022

Nov 07, 2022

BUY
$0.13 - $76.84 $1,862 - $1.1 Million
14,324 Added 54.77%
40,478 $2.88 Million
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $165,065 - $181,794
-2,273 Reduced 8.0%
26,154 $2.01 Million
Q1 2022

May 04, 2022

BUY
$61.48 - $73.72 $812,519 - $974,283
13,216 Added 86.88%
28,427 $2.08 Million
Q4 2021

Mar 08, 2022

BUY
$53.63 - $62.52 $815,765 - $950,991
15,211 New
15,211 $948,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Arvest Trust CO N A Portfolio

Follow Arvest Trust CO N A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arvest Trust CO N A, based on Form 13F filings with the SEC.

News

Stay updated on Arvest Trust CO N A with notifications on news.